Keith D. Hall
Chief Operating Officer chez Genopis, Inc.
Profil
Keith D.
Hall is currently the Chief Operating Officer at Genopis, Inc. Prior to this, he was the Vice President-Operations at Vical, Inc. from 2003 to 2018 and the Manufacturing Director at Agennix, Inc. from 2000 to 2003.
He also worked as a Senior Manager-Quality Control at Valentis, Inc. from 1994 to 2000.
Mr. Hall received his undergraduate degree from the University of California, Santa Barbara and his MBA from C.
T.
Bauer College of Business.
Postes actifs de Keith D. Hall
| Sociétés | Poste | Début |
|---|---|---|
Genopis, Inc.
 Genopis, Inc. Pharmaceuticals: MajorHealth Technology Genopis, Inc. engages in the provision of biotech and pharmaceutical services. The company is headquartered in San Diego, CA. | Chief Operating Officer | 01/08/2018 |
Anciens postes connus de Keith D. Hall
| Sociétés | Poste | Fin |
|---|---|---|
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Operating Officer | 01/08/2018 |
Agennix, Inc.
 Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01/01/2003 |
Valentis, Inc.
 Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Corporate Officer/Principal | 01/01/2000 |
Formation de Keith D. Hall
| University of California, Santa Barbara | Undergraduate Degree |
| C. T. Bauer College of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Agennix, Inc.
Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Health Technology |
Genopis, Inc.
Genopis, Inc. Pharmaceuticals: MajorHealth Technology Genopis, Inc. engages in the provision of biotech and pharmaceutical services. The company is headquartered in San Diego, CA. | Health Technology |
